Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06251323 · ClinicalTrials.gov registry record · NA

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

A NA study of Diabetes Mellitus, Type 2, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
119,680
Enrollment target
4
Study locations

NCT06251323: Recruiting NA study of Diabetes Mellitus, Type 2, sponsored by Stanford University.

NCT06251323 is a NA study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Stanford University. The registered enrollment target is 119,680 participants, above the 4,141-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (2790% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06251323, a NA study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
119,680 participants
Enrollment target
4
Study locations

Study Summary

Sixteen institutions will be selected from a HRSA uniform data system and have data collected for up to 3 years. Eight institutions will begin the iPATH practice transformation during year one, the other eight institutions will begin iPATH in year two. FQHC administrators, clinicians and staff will be enrolled to participate in the iPATH transformation in their clinic and will participate in qualitative interviews. Patient HbA1c data from the clinics will be collected for comparative data analysis during each year of the study.

Primary Outcome

Percent poorly controlled diabetes (A1c\>9%)

Conditions Studied

Interventions

  • OTHER iPATH implementation approach

Study Locations (4)

California

  • Board of Trustees of the Leland Stanford Junior University - Stanford

Massachusetts

  • President and Fellows of Harvard College, T.H. Chan School - Boston

Ohio

  • The Ohio State University - Columbus

Puerto Rico

  • Impactivo, LLC. - San Juan

Trial Details

FieldValue
Enrollment Target 119,680 participants
Start Date 2025-09-30
Est. Completion 2028-01-31
Phase NA
Stanford University

1,744 total trials

What NCT06251323 shows while recruiting

NCT06251323 is an interventional study that assigns participants to a tested intervention. Its 119,680 participants enrollment target places it among the larger protocols in the corpus, above the 4,141-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (2790% higher).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which iPATH implementation approach is the first listed.

NCT06251323 reports a single indexed study location in California, Massachusetts, Ohio.

Frequently Asked Questions

What is clinical trial NCT06251323 about?

NCT06251323 is a clinical study titled "Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)". Sixteen institutions will be selected from a HRSA uniform data system and have data collected for up to 3 years. Eight institutions will begin the iPATH practice transformation during year one, the other eight institutions will begin iPATH in year two. FQHC administrators, clinicians and staff will ...

What is the current status of trial NCT06251323?

This trial is currently recruiting. It is a NA study. The enrollment target is 119,680 participants. The study started on 2025-09-30. Estimated completion is 2028-01-31.

What conditions does trial NCT06251323 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT06251323?

The interventions under investigation include: iPATH implementation approach (OTHER).

Who is sponsoring clinical trial NCT06251323?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06251323 being conducted?

This trial has 4 study locations across California, Massachusetts, Ohio, Puerto Rico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06251323's enrollment target sits among peer trials

119,680 4th of 348 higher than 345 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03897374 · 120,000 participants

    Strategic Targeting for Optimal Prevention of Cancer

  • NCT06608758 · 120,000 participants

    End Diagnostic Overshadowing:Addressing Ableism in Diagnoses

  • NCT02693509 · 128,026 participants

    Get With The Guidelines-Heart Failure Registry

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06251323, the US trial registry maintained by the National Library of Medicine. NCT06251323 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.